Latest Conference Articles

Most clinicians are not considering poor home air exposure when treating persistent asthma or airway disease, Raju explains. That may be making a difference in outcomes.

CHEST 2025 data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

Rali highlights a series of randomized, controlled trials that could reinvigorate the recently stagnant field of PE treatment development.

Ezekowitz spotlights improvement in cardiovascular mortality and heart failure hospitalization despite a failure to achieve the primary endpoint of VICTOR.

Witteles highlights the uniform improvement after the tafamidis and vutrisiran arms were both moved to the same vutrisiran dose.

An exploratory analysis of the ATTRibute-CM trial spotlighted acoramidis’s superior efficacy in lowering CVD-related risks versus placebo.

This interview segment with Irvine highlighted his team’s data presented at EADV regarding children 6-11 years with atopic dermatitis on dupilumab.

In this interview, improvements observed in children 6-11 years with severe atopic dermatitis following dupilumab use were spotlighted.

Desai details recent advancements in medicine and invasive treatments while reminding clinicians of what can still be done to protect patients.

This EADV interview features a discussion of data from the DISCOVER study on the effects of dupilumab (Dupixent) on atopic dermatitis in skin of color.

Cedars discusses the difficulties in diagnosing heart failure in this population and how clinicians can provide their patients with better care.

This interview from EADV highlights recent data from PRIME and PRIME2 on the effects of dupilumab (Dupixent) on itch and pain in prurigo nodularis.

A prespecified secondary analysis revealed no difference in male and female patients’ responses to tirzepatide in obesity-related HFpEF.

Peters emphasized how the new findings reinforce treatment strategies for chronic rhinosinusitis with nasal polyps.

Bhatt discussed the latest data from a post-hoc analysis of the BOREAS and NOTUS trials.

Read about groundbreaking FDA decisions, exciting new heart failure research, and more.

This set of interviews collects perspectives from 11 leading clinicians in the heart failure field, cataloguing the biggest news from 2025.

Counting down the most impactful news at major medical meetings, it’s the HCPLive Five! This episode focuses on 5 key dermatology updates from EADV.

During this EADV interview, Lebwohl speaks to some of the most recent developments in the psoriasis research space.

Hanania discussed the rationale and findings of the BOREAS and NOTUS studies.

In this set of interviews, 6 leaders in the field of dermatology highlight their experiences at the 2025 EADV Congress.

Le discusses methods by which clinicians can ease the financial burden of obtaining and adhering to medication for their patients.

The investigative therapy from Windtree Therapeutics also maintained a favorable safety and tolerability profile versus placebo.

In this interview at EADV, Bernstein highlights dupilumab’s impact on urticaria activity in individuals with chronic spontaneous urticaria (CSU).

Explore the evolving landscape of heart failure endpoints, focusing on the significance of oral diuretic intensification in outpatient care.

Recent analyses detail the ongoing risk of hyperkalemia in heart failure patients, highlighting the importance of optimal medication dosing.

An analysis of data from the HELIOS-B trial indicated an overall reduction in GI events among the vutrisiran cohort compared to those receiving placebo.

100% of included participants were successfully defibrillated and exhibited 6-month improvements or stability in the majority of patients.